The Onco-Nephrology Field : The Role of Personalized Chemotherapy to Prevent Kidney Damage
In recent years, the onco-nephrology field has acquired a relevant role in internal medicine due to the growing number of cases of renal dysfunction that have been observed in cancer patients. This clinical complication can be induced by the tumor itself (for example, due to obstructive phenomena affecting the excretory tract or by neoplastic dissemination) or by chemotherapy, as it is potentially nephrotoxic. Kidney damage can manifest as acute kidney injury or represent a worsening of pre-existing chronic kidney disease. In cancer patients, physicians should try to set preventive strategies to safeguard the renal function, avoiding the concomitant use of nephrotoxic drugs, personalizing the dose of chemotherapy according to the glomerular filtration rate (GFR) and using an appropriate hydration therapy in combination with nephroprotective compounds. To prevent renal dysfunction, a new possible tool useful in the field of onco-nephrology would be the development of a personalized algorithm for the patient based on body composition parameters, gender, nutritional status, GFR and genetic polymorphisms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Cancers - 15(2023), 8 vom: 12. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Noce, Annalisa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute kidney injury |
|---|
| Anmerkungen: |
Date Revised 19.05.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers15082254 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356928349 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356928349 | ||
| 003 | DE-627 | ||
| 005 | 20231226071510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers15082254 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1189.xml |
| 035 | |a (DE-627)NLM356928349 | ||
| 035 | |a (NLM)37190182 | ||
| 035 | |a (PII)2254 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Noce, Annalisa |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Onco-Nephrology Field |b The Role of Personalized Chemotherapy to Prevent Kidney Damage |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.05.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a In recent years, the onco-nephrology field has acquired a relevant role in internal medicine due to the growing number of cases of renal dysfunction that have been observed in cancer patients. This clinical complication can be induced by the tumor itself (for example, due to obstructive phenomena affecting the excretory tract or by neoplastic dissemination) or by chemotherapy, as it is potentially nephrotoxic. Kidney damage can manifest as acute kidney injury or represent a worsening of pre-existing chronic kidney disease. In cancer patients, physicians should try to set preventive strategies to safeguard the renal function, avoiding the concomitant use of nephrotoxic drugs, personalizing the dose of chemotherapy according to the glomerular filtration rate (GFR) and using an appropriate hydration therapy in combination with nephroprotective compounds. To prevent renal dysfunction, a new possible tool useful in the field of onco-nephrology would be the development of a personalized algorithm for the patient based on body composition parameters, gender, nutritional status, GFR and genetic polymorphisms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a acute kidney injury | |
| 650 | 4 | |a chemotherapeutic drugs | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a predictive algorithm | |
| 650 | 4 | |a renal insufficiency | |
| 700 | 1 | |a Marrone, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Di Lauro, Manuela |e verfasserin |4 aut | |
| 700 | 1 | |a Mitterhofer, Anna Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Ceravolo, Maria Josè |e verfasserin |4 aut | |
| 700 | 1 | |a Di Daniele, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Manenti, Guglielmo |e verfasserin |4 aut | |
| 700 | 1 | |a De Lorenzo, Antonino |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 15(2023), 8 vom: 12. Apr. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:8 |g day:12 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers15082254 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 8 |b 12 |c 04 | ||